MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Morales, María Luz, Arenas, Alicia, Ortiz-Ruiz, Alejandra, Leivas, Alejandra, Rapado, Inmaculada, Rodríguez-García, Alba, Castro, Nerea, Zagorac, Ivana, Quintela-Fandino, Miguel, Gómez-López, Gonzalo, Gallardo, Miguel, Ayala, Rosa, Linares, María, Martínez-López, Joaquín
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6901485/
https://ncbi.nlm.nih.gov/pubmed/31819100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-54901-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares